TNFSF10 and colorectal cancer: Importantly, to our knowledge for the first time, we have demonstrated that combinatorial treatment with 17-AAG and TRAIL resulted in an improved response compared to the individual agents in vivo in two TRAIL-resistant human colorectal cancer xenograft models.